Celgene tries to convince investors with 2-billion-dollar program

The pharmaceutical group Celgene has announced it plans to launch a stock repurchase program worth at least $2bn, in the hope to increase back its stock value (Nasdaq), which has decreased over 30% since the beginning of the year and 45% since October 2017.